Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year High - Time to Buy?

Key Points

• 52-week high: Shares hit a new 52-week high of $47.26 (last $47.15) and were up about 5.3%, giving the company a market cap of roughly $2.85 billion and a negative P/E of -25.66.
• Mixed analyst ratings: Five analysts rate the stock a Buy and one a Sell, producing a consensus "Moderate Buy" and $43.40 price target, though HC Wainwright raised its target to $56 and Mizuho to $45.
• Fundamentals and insider activity: The company missed quarterly EPS (loss of $0.48 vs. $0.42 expected), insiders sold about 37,460 shares in the past 90 days (insiders own 25.9%), and institutional/hedge funds reportedly own ~95% of the stock.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) hit a new 52-week high on Friday . The company traded as high as $47.26 and last traded at $47.1530, with a volume of 72470 shares changing hands. The stock had previously closed at $45.34.

Analyst Ratings Changes

ELVN has been the topic of several recent research reports. Wall Street Zen lowered shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, February 28th. HC Wainwright upped their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a "buy" rating in a report on Thursday, March 26th. Mizuho increased their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an "outperform" rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $43.40.

Enliven Therapeutics Trading Up 5.3%

The company has a market capitalization of $2.85 billion, a price-to-earnings ratio of -25.66 and a beta of 0.26. The company's 50 day simple moving average is $32.79 and its 200-day simple moving average is $25.15.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Activity at Enliven Therapeutics

In related news, Director Richard A. Heyman sold 1,230 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director directly owned 22,647 shares in the company, valued at approximately $592,898.46. This represents a 5.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph P. Lyssikatos sold 20,000 shares of Enliven Therapeutics stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $26.75, for a total value of $535,000.00. Following the completion of the sale, the insider owned 745,188 shares of the company's stock, valued at $19,933,779. This trade represents a 2.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 37,460 shares of company stock worth $1,041,104. 25.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ELVN. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Enliven Therapeutics during the fourth quarter valued at about $83,000. Quantbot Technologies LP increased its stake in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Enliven Therapeutics in the 4th quarter worth about $95,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.